FDA Approves New Treatment for Gastrointestinal and Kidney Cancer
Monday, 30 January 2006
The Food and Drug Administration (FDA) today announced approval of Sutent (sunitinib), a new targeted anti-cancer treatment for patients with gastrointestinal stromal tumors (GIST), a rare stomach cancer, and advanced kidney cancer.
read more
|
Asymptomatic, Incidentally Detected Renal Cell Carcinomas Demonstrate Are Of Lower Stage, Grade, And Associated With An Improved Survival
Friday, 27 January 2006
BERKELEY, CA (UroToday.com) - A group from Iceland examined their entire experience with renal cell carcinoma (RCC) over a 30 year period (1971-2000) to determine factors important in predicting outcome.
read more
|
Efficacy And Safety Of Fast Track Recovery Strategy For Patients Undergoing Laparoscopic Nephrectomy
Friday, 27 January 2006
BERKELEY, CA (UroToday.com) - More attention is being directed to creating care pathways for surgical patients to facilitate their peri- and post-operative care, reduce healthcare costs, and most importantly, increase patient satisfaction.1,2
read more
|
Good Outcomes Attainable Using Kidney Transplants From Older Donors
Friday, 27 January 2006
NEW YORK (Reuters Health) - Excellent long-term outcomes can be achieved using kidney transplants from donors older than 60 years of age, provided that the grafts are histologically evaluated prior to implantation, according to a report in The New England Journal of Medicine for January 26.
read more
|
Clinical Manifestations Of Renal Oncocytoma
Thursday, 26 January 2006
BERKELEY, CA (UroToday.com) - Oncocytoma, first described in 1942, is thought to be a benign renal tumor that originates from the intercalated cells of the collecting duct and represents 3-7% of renal tumors.
read more
|
Second-Line Therapy In Metastatic Renal Cell Carcinoma Nears Reality
Thursday, 26 January 2006
NEW YORK (Reuters Health) - A multi-targeted tyrosine kinase inhibitor of receptors for vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) shows significant anti-tumor effects in patients with metastatic renal cell carcinoma.
read more
|
Carbonic Anhydrase IX: An Important Marker Of Tumor Virulence In Renal Cell Carcinoma
Wednesday, 25 January 2006
BERKELEY, CA (UroToday.com) - Carbonic Anhydrase IX (CAIX) is a membrane bound zinc metalloenzyme that has been shown to be overexpressed in renal cell carcinoma (RCC).
read more
|
Rate Of Incidentally Detected Renal Cancer Up In Iceland, As Is Survival
Tuesday, 24 January 2006
NEW YORK (Reuters Health) - In Iceland, an almost threefold increase in incidentally detected renal cell carcinoma (RCC) in the past 30 years, due in large part to more widespread use of abdominal ultrasound and CT, has been associated with improved survival, according to a new study.
read more
|
CT Angiograms To Detect Pulmonary Embolus: What To Do With An Indeterminant Interpretation
Monday, 23 January 2006
BERKELEY, CA (UroToday.com) - Pulmonary embolus (PE) can be a devastating complication following pelvic surgery. Anti-thromboembolic measures such as TED hose, compression boots, and subcutaneous anticoagulants are frequently employed in the perioperative period in an attempt to decrease the incidence of deep venous thrombosis (DVT) and PE.
read more
|
√ The Role Of Percutaneous Biopsy For The Indeterminant Renal Mass Revisited
Thursday, 19 January 2006
√ Editor's Pick:
read more
|
Contrast-Enhanced Ultrasonography In The Diagnosis Of Solid Renal Tumors
Tuesday, 17 January 2006
BERKELEY, CA (UroToday.com) - A variety of different imaging modalities can be used to image a renal mass, including CT scanning, MRI, as well as ultrasound.
read more
|
Novel Markers Of Progression In Renal Cell Carcinoma: Immunosuppressive Acidic Protein Detects High Nuclear Grade In Localize Renal Cell Carcinoma
Friday, 13 January 2006
BERKELEY, CA (UroToday.com) - Stratification of risk of progression in patients with localized renal cell carcinoma (RCC) allows tailoring of surveillance protocols and identifying patients at high risk of relapse for adjuvant therapy clinical trials.
read more
|
Erythrocyte Sedimentation Rate: An Independent Prognostic Variable In Renal Cell Carcinoma Patients
Thursday, 12 January 2006
BERKELEY, CA (UroToday.com) - Erythrocyte sedimentation rate (ESR) is thought to be a non-specific, acute phase reactant that can be elevated in a variety of pathophysiologic conditions, including inflammatory processes, infections, and malignancy, especially in the setting of metastatic disease.
read more
|
Are Patients With One Genitourinary Malignancy More Likely To Harbor Another?
Tuesday, 10 January 2006
BERKELEY, CA (UroToday.com) - Not uncommonly in urologic practice, a patient may harbor more than one primary cancer of genitourinary origin.
read more
|
Moderate Drinking May Be Linked To Lower Renal Cancer Risk
Wednesday, 04 January 2006
NEW YORK (Reuters Health) - Moderate alcohol intake appears to be associated with a decreased risk of renal cell carcinoma in middle-age and older women, according to the results of a prospective study conducted in Sweden.
read more
|
FDA Approves Nexavar® For Treatment Of Patients With Advanced Kidney Cancer
Wednesday, 21 December 2005
WEST HAVEN, Conn., and EMERYVILLE, Calif. ? Dec. 20, 2005 - Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma (RCC), or kidney cancer.
read more
|
Safe Resection Of Intra-Atrial Renal Cell Carcinoma Vena Cava Thrombi (T3c) Without The Need For Median Sternotomy, Cardio-pulmonary Bypass And Hypothermic Arrest, Or Veno-Venous Bypass
Monday, 19 December 2005
BERKELEY, CA (UroToday.com) - Resection of intra-atrial vena cava thrombi (T3c disease) from renal cell carcinoma probably represents the most surgically daunting case to confront the practicing urologic oncologist.
read more
|
The Complication Of Renal Artery Pseudoaneurysm Following Laparoscopic Partial Nephrectomy Reviewed
Friday, 16 December 2005
BERKELEY, CA (UroToday.com) - Partial nephrectomy has become standard of care as a nephron sparing option in the properly selected patient with a T1 tumor.
read more
|
The Complication Of Renal Artery Pseudoaneurysm Following Laparoscopic Partial Nephrectomy Reviewed
Friday, 16 December 2005
BERKELEY, CA (UroToday.com) - Partial nephrectomy has become standard of care as a nephron sparing option in the properly selected patient with a T1 tumor.
read more
|
Three Factors Predict Stem Cell Transplant Success In Renal Cancer
Wednesday, 14 December 2005
NEW YORK (Reuters Health) - Allogeneic hematopoietic stem cell transplantation from a compatible sibling donor can induce a high rate of response in metastatic renal cancer, but may have side effects and toxicities.
read more
|
A Novel Method For Partial Nephrectomy: Selective Renal Parenchymal Clamping
Tuesday, 13 December 2005
BERKELEY, CA (UroToday.com) - Partial nephrectomy has been proven to be oncologically equivalent to radical nephrectomy for appropriately selected patients with renal tumors.
read more
|
Multifocal Papillary Renal Cell Carcinoma: Molecular Genetic Testing Reveals A Different Biology For Multifocality In Papillary Renal Cell Carcinoma As Compared To Conventional (Clear Cell) Renal Cell Carcinoma
Monday, 05 December 2005
BERKELEY, CA (UroToday.com) - Multifocal tumors are found in 7-25% of radical nephrectomy specimens, with papillary histology the most common type associated with multifocality.
read more
|
Can Multilocular Cystic Renal Cell Carcinomas Be Differentiated From Clear Cell Renal Cell Carcinomas With Cystic Change Based On Preoperative Radiographic Imaging?
Friday, 02 December 2005
BERKELEY, CA (UroToday.com) - Multilocular cystic renal cell carcinomas (MCRCC) are rare (1-4%) variants of clear cell renal cell carcinomas that demonstrate a relatively innocuous natural history when compared to other histologic subtypes.
read more
|
BJUI Mini Reviews - Comparison of Cryoablation, Radiofrequency Ablation and High-Intensity Focused Ultrasound for Treating Small Renal Tumours
Thursday, 01 December 2005
Herein, this article will discuss the currently available data
on the efficacy and morbidity rates of the
most promising ablative technologies, i.e.
cryoablation, radiofrequency ablation (RFA)
and high-intensity focused ultrasound (HIFU).
Login to read more...
|
Assessing Prognosis In Patients With Metastatic Conventional Renal Cell Carcinoma: Development Of A Scoring Algorithm To Stratify Patients For Clinical Trials
Tuesday, 15 November 2005
BERKELEY, CA (UroToday.com) - While the median survival for patients with metastatic renal cell carcinoma is reported to be one year, it remains clear that not all patients with metastatic disease behave the same.
read more
|
Long-Term Survival Analysis After Laparoscopic Radical Nephrectomy
Friday, 11 November 2005
BERKELEY, CA (UroToday.com) - It has now been 15 years since the first reported laparoscopic total nephrectomy for renal tumor.
read more
|
Fuhrman?s Nuclear Grade Is The Most Important Predictor Of Survival and Recurrence Free Survival In Patients With Localized Conventional (Clear Cell) Renal Cell Carcinoma
Wednesday, 09 November 2005
BERKELEY, CA (UroToday.com) - Two recent studies examining prognostic variables in localized renal cell carcinoma have demonstrated that Fuhrman's grade appears to be the most important predictor of survival and recurrence free survival for patients with localized disease undergoing curative surgery.
Login to read more...
|
Renal Cell Carcinoma Developing In Renal Transplant Allografts: Nephron Sparing Approaches Provide Oncological Control and Maintain Graft Function
Monday, 07 November 2005
BERKELEY, CA (UroToday.com) - Renal transplantation has improved the outlook for thousands of patients with end stage renal disease, providing improved quality of life, improved survival, and relief from the burdens of hemodialysis.
read more
|
An Update Of The Bosniak Renal Cyst Classification System
Friday, 04 November 2005
BERKELEY, CA (UroToday.com) - Despite the increasing ease in treating renal masses by laparoscopic or percutaneous intervention, the adage still remains: "first make a diagnosis, then make a treatment".
read more
|
Investigator Presents Update on Phase III Nexavar® Trial in Patients with Advanced Kidney Cancer
Thursday, 03 November 2005
Paris, France ? Nov. 03, 2005 - Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported that Dr. Bernard Escudier provided an update on the Nexavar® (sorafenib tosylate) Tablets Phase III trial in patients with advanced renal cell carcinoma (RCC), or kidney cancer during the thirteenth European Cancer Conference (ECCO).
read more
|
Palliative Radiation Therapy Can Provide Significant Symptom Relief In Patients With Metastatic Renal Cell Carcinoma
Friday, 28 October 2005
BERKELEY, CA (UroToday.com) - Current dogma is that renal cell carcinoma is radioresistant and therefore treatment approaches involving radiotherapy have been thought largely ineffective.
read more
|
Bayer And Onyx Announce Nexavar® (Sorafenib Tosylate) Tablets As Global Trade Name For Investigational Cancer Treatment
Friday, 28 October 2005
WEST HAVEN, Conn. & EMERYVILLE, Calif. ? Oct. 28, 2005 - Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the selection of Nexavar® (sorafenib tosylate) Tablets as the global trade name for sorafenib, the oral investigational drug under FDA review for the treatment of advanced renal cell carcinoma (RCC), or kidney cancer.
read more
|
Targeted Therapy Improves Response Rates In Patients With Metastatic Renal Cell Carcinoma: Results Of A Phase II Multicenter Trial Evaluating The Combination Of Bevacizumab And Erlotinib
Tuesday, 25 October 2005
BERKELEY, CA (UroToday.com) - In the past, systemic therapies for metastatic renal cell carcinoma, such as interleukin 2 and interferon, have been largely ineffective and associated with significant toxicity.
read more
|
Approach To Urologic Malignancies In Solid Organ Transplant Patients
Friday, 21 October 2005
BERKELEY, CA (UroToday.com) - Patients with solid organ transplants are at risk for tumor development in their native as well as transplanted organs.
read more
|
Nonmyeloablative Allogeneic Stem Cell Transplantation For Metastatic Renal Cell Carcinoma: Refining Patient Selection
Thursday, 20 October 2005
BERKELEY, CA (UroToday.com) - Nonmyeloablative allogeneic stem cell transplantation as a therapy for metastatic renal cell carcinoma remains a controversial treatment strategy for a disease where there seems to be multiple new treatment approaches but no clear best therapeutic approach.
read more
|
Tissue Specific Markers Of Prognosis In Renal Cell Carcinoma: B7-H1 Glycoprotein
Wednesday, 19 October 2005
BERKELEY, CA (UroToday.com) - Renal cell carcinoma (RCC) remains one of the few tumors responsive to immunotherapeutic strategies in the setting of metastatic disease; however response rates with this approach remain only in the range of 20%.
read more
|
Do Pulmonary Artery (Swann Ganz) Catheters Really Help In the Management of Critically Ill Patients: Results of a Meta-Analysis of 13 Randomized Clinical Trials?
Monday, 17 October 2005
BERKELEY, CA (UroToday.com) - Pulmonary artery catheters (PAC) are frequently employed in the intensive care setting in critically ill patients to diagnose various disease and physiologic states, with the hope that the data gained from PAC placement may improve patient management.
read more
|
Comparison Of Laparoscopic Partial Nephrectomy and Laparoscopic Cryoablation For Small Renal Tumors Reported
Tuesday, 11 October 2005
BERKELEY, CA (UroToday.com) - Recent years have witnessed the emergence of a variety of minimally invasive nephron-sparing options for the select patient with a small renal tumor.
read more
|
Comparison Of Laparoscopic Partial Nephrectomy and Laparoscopic Cryoablation For Small Renal Tumors Reported
Tuesday, 11 October 2005
BERKELEY, CA (UroToday.com) - Recent years have witnessed the emergence of a variety of minimally invasive nephron-sparing options for the select patient with a small renal tumor.
read more
|
Adjuvant Therapy For Locally Advanced Renal Cell Carcinoma At High Risk Of Relapse Following Surgery
Thursday, 06 October 2005
BERKELEY, CA (UroToday.com) - The standard of care for patients with locally advanced renal cell carcinoma that are resected to no evidence of disease is observation.
read more
|
Molecular Classification Of Renal Cell Carcinoma (RCC) Histology: Using RNA Expression Ratios To Distinguish Between Different Subtypes Of RCC And Benign From Malignant Renal Neoplasms
Wednesday, 05 October 2005
BERKELEY, CA (UroToday Inc.) - In this study out of Cornell University, Chen and colleagues report on their experience with molecular phenotyping of renal neoplasms using quantitative reverse transcription-PCR (qRT-PCR) of both fresh frozen and paraffin imbedded renal tumor specimens.
read more
|
Laparoscopic Renal-Adrenal Surgery In Patients On Oral Anticoagulant Therapy
Friday, 30 September 2005
BERKELEY, CA (UroToday Inc.) - The Johns Hopkins group retrospectively evaluated bleeding complications with laparoscopic renal-adrenal surgery in patients on chronic anticoagulant therapy.
read more
|
Is T3a Renal Cell Carcinoma Underreported And Misclassified In The Current (2002) AJCC TNM Classification System?
Tuesday, 27 September 2005
BERKELEY, CA (UroToday Inc.) - The American Joint Committee on Cancer (AJCC) classifies T3a renal cell carcinoma as invasion of the perinephric fat, adrenal, or renal sinus.
read more
|
Laparoscopic Radical Nephrectomy: The Standard Of Care For Localized Renal Cell Carcinoma
Friday, 23 September 2005
BERKELEY, CA (UroToday Inc.) - Laparoscopic nephrectomy for localized renal cell carcinoma was first described by Ralph Clayman in 1991.
read more
|
Laparoscopic Radical Nephrectomy: The Standard Of Care For Localized Renal Cell Carcinoma
Friday, 23 September 2005
BERKELEY, CA (UroToday Inc.) - Laparoscopic nephrectomy for localized renal cell carcinoma was first described by Ralph Clayman in 1991.
read more
|
Phase I Data On Antisense Oligonucleotide To Clusterin Reported
Thursday, 22 September 2005
BERKELEY, CA (UroToday Inc.) - Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers resistance to treatments.
read more
|
How Best To Predict The Risk Of Recurrence Following Surgery For Clinically Localized And Locally Advanced Renal Cell Carcinoma
Wednesday, 21 September 2005
BERKELEY, CA (UroToday Inc.) - A study by Cindolo et al. sought to evaluate the discriminatory and prognostic rigor of four models that predict outcome for patients with non-metastatic renal cell carcinoma based on preoperative and/or postoperative clinical and pathologic variables.
read more
|
Urologists Should Play Integral Role In Palliative Care Of Patients
Tuesday, 20 September 2005
BERKELEY, CA (UroToday Inc.) - Genitourinary cancer accounted for 21% of all new cancer cases in 2003 and resulted in 16% of cancer deaths.
read more
|
Bayer and Onyx Announce FDA Acceptance of New Drug Application for Sorafenib for Individuals With Advanced Renal Cell Carcinoma
Wednesday, 14 September 2005
West Haven, CT and Emeryville, CA ? September 14, 2005 ? Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New Drug Application (NDA) for sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma (RCC), or kidney cancer, has been accepted for review and granted Priority Review status by the U.S. Food and Drug Administration (FDA).
read more
|
BJUI Mini Reviews - A Perspective on Protein Profiling of Blood
Thursday, 01 September 2005
This review examines the common working methods for profiling biological samples, concluding with a description of our current work and a description of the problems that we are currently attempting to address.
Login to read more...
|
Renal Cancer 
